Tuesday, February 19th, 2008...5:30 am
Cleveland BioLabs Protectan CBLB502 Demonstrates Significant Reduction of Adverse Effects of Chemotherapeutic Drug in … (Marketwire via Yahoo! Finance)
Jump to Comments
Cleveland BioLabs Protectan CBLB612 Demonstrates Significant Reduction of Myelosuppression in Mouse Model of … (Marketwire via Yahoo! Finance) Cleveland BioLabs Protectan CBLB612 Demonstrates Significant Reduction Of Myelosuppression In Mouse Model Of … (Medical News Today) Cleveland BioLabs Protectan CBLB502 Demonstrates Strong Mitigation Of Hematopoietic Damage at 48 Hours Post-Exposure … (Marketwire via Yahoo! Finance) Cleveland BioLabs reports positive effects of chemotherapeutic drug (Pharmaceutical Business Review) Cleveland BioLabs to Present Protectan CBLB502 at 2007 BARDA Industry Day (Marketwire via Yahoo! Finance)
Cleveland BioLabs, Inc. today announced results of a study demonstrating Protectan CBLB502’s ability to reduce the side effects of a chemotherapeutic drug, cisplatinum, broadly used for treatment of ovarian, endometrial, head and neck, lung, stomach and other types of cancer.
Full story at cleveland-akron news
Share your Opinion